A New Edge Biosystems

Mark Twain is purported to have once said “the reports of my death have been greatly exaggerated” and the same might be true for the “gold standard” DNA sequencing technology that many refer to as CE or Sanger sequencing.  CE sequencing is experiencing a renaissance, thanks in great part to the technology that was purported to hasten its demise – NGS.  As NGS is employed more extensively across the globe and in more applications, especially in clinical diagnostic applications, the need to verify or confirm the large number of variants generated from whole genome sequencing or whole exome sequencing tests is increasing concomitantly.  CE sequencing, still considered the gold standard by the community (including the FDA), is the go to technology for sequence confirmation. Edge Biosystems, with its Performa® BigDye Terminator Removal (DTR) product lines, is benefiting from this renaissance in CE sequencing, so much so, that private equity firm StoneCalibre acquired EdgeBio in July of this year. This acquisition will enable EdgeBio to re-focus on its market leading DTR technology and expand its product portfolio. As Brian Wall, StoneCalibre Founder and CEO said "We believe EdgeBio will continue to build on its tradition of providing high-quality, easy-to-use products to its global customer base and serve as a strong platform for future growth".  We hope that you will like what you experience with the new EdgeBio.